Early inhaled budesonide in extremely preterm infants decreases long-term respiratory morbidity
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F20%3A10411481" target="_blank" >RIV/00216208:11110/20:10411481 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/20:10411481
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=pKCyuM0nhO" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=pKCyuM0nhO</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/ppul.24704" target="_blank" >10.1002/ppul.24704</a>
Alternative languages
Result language
angličtina
Original language name
Early inhaled budesonide in extremely preterm infants decreases long-term respiratory morbidity
Original language description
Background: There is no strict correlation between early bronchopulmonary dysplasia and long-term respiratory disease. Early inhaled corticosteroids seem to reduce the incidence of bronchopulmonary dysplasia, but the long-term outcome remains unknown. Research Question: The aim of this study was to evaluate the effect of early inhaled corticosteroids on chronic respiratory morbidity. Methods: Fifty-nine survivors from the Prague cohort included in Neonatal European Study of Inhaled Steroids underwent further follow-up comprising of respiratory morbidity monitoring during the first 2 years of life followed by objective lung function testing performed at the age of 5.9 years (range 5-7 years). Both outcomes were pursued and finalized before the unblinding of budesonide subgroups. Results: Fifty randomized (budesonide vs placebo group, 56% vs 44%) survivors were included in the study. Spirometry was successfully performed in 48 children. No statistically significant differences were found in the lung function test (forced expiratory flow [FEF] - FEF75, FEF50, FEF25, and FEF25-75; FEV1, forced vital capacity [FVC], FEV1/FVC) although mild trend to the improvement of expiratory flow pattern was observed in the budesonide group (median z -score of FEV1/FVC -0.376 vs -0.983, P = .13; median z -score of FEF25-75 -1.004 vs -1.458, P = .13; median z -score of FEF75 -0.527 vs -0.996, P = .17). Children assigned to budesonide had a significantly lower rate of symptoms of chronic lung disease (34.6% vs 68.2%; P = .04) than children assigned to placebo. Interpretation: Our study suggests that early inhaled budesonide was associated with the trend to the improvement of functional lung parameters and with a lower rate of symptoms of chronic lung disease within the first 2 years of life.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30209 - Paediatrics
Result continuities
Project
—
Continuities
O - Projekt operacniho programu
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Pediatric Pulmonology
ISSN
8755-6863
e-ISSN
—
Volume of the periodical
55
Issue of the periodical within the volume
5
Country of publishing house
US - UNITED STATES
Number of pages
7
Pages from-to
1124-1130
UT code for WoS article
000517352700001
EID of the result in the Scopus database
2-s2.0-85081016882